Developmental toxicity assessment of d,l-methylphenidate and d-methylphenidate in rats and rabbits

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 83, Issue 5, 2008, Pages 489-501

  Beckman, David A ^a   Schneider, Marilynn ^a   Youreneff, Maureen ^a   Tse, Francis L S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Developmental toxicity; Embryo fetal development; Methylphenidate; Rabbit; Rat; Teratogen

Indexed keywords

METHYLPHENIDATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRTH DEFECT; BONE MALFORMATION; BREATHING; CONTROLLED STUDY; DRUG TISSUE LEVEL; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; EXPERIMENTAL RABBIT; FEMALE; FOOD INTAKE; GESTATIONAL AGE; LIMB MALFORMATION; MASTICATION; MYDRIASIS; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; REPRODUCTIVE TOXICITY; SALIVATION; SPINA BIFIDA; TERATOGENICITY; TOXICITY TESTING; TOXICOKINETICS; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; EMBRYONIC DEVELOPMENT; FEMALE; HINDLIMB; MALE; METHYLPHENIDATE; RABBITS; RATS; RATS, WISTAR; RESPIRATION; SALIVATION; SPINAL DYSRAPHISM;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 55449089294     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20168     Document Type: Article

References (22)

1. Aoyama T, Kotaki H, Sawada Y, Iga T. 1996. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology (Berl) 127:117-122.
2. Bakhtiar R, Tse FL. 2004. Toxicokinetic assessment of methylphenidate (Ritalin®) enantiomers in pregnant rats and rabbits. Biomed Chromatogr 18(5):275-281.
3. Carney EW, Kimmel CA. 2007. Interpretation of skeletal variations for human risk assessment: Delayed ossification and wavy ribs. Birth Defects Res 80:473-496.
4. CERHR [Center for the Evaluation of Risks to Human Reproduction, National Toxicology Program, US Department of Health and Human Services]. 2005. NTP-CERHR Monograph on the potential human reproductive and developmental effects of methylphenidate. NIH Publication No. 05-4473.
5. Davids E, Zhang K, Tarazi FI, Baldessarini RJ. 2002. Stereoselective ef fects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl) 160:92-98.
6. Dunnett CW. 1955. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096-1121.
7. Dunnett CW. 1964. New tables for multiple comparisons with a control. Biometrics 20:482-491.
8. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, et al. 2000. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther 295:51-57.
9. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. 1998. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 279:1100-1107.
10. Heal DJ, Pierce DM. 2006. Methylphenidate and its isomers: Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 20:713-738.
11. International Conference on Harmonization. Guidelines on detection of toxicity to reproduction for medicinal products; availability; notice. 1994, Sept 22. Fed Reg 59:183.
12. Mehta CR, Patel NR, Tsiatis AA. 1984. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-8825.
13. Nishimura M, Iizuka M, Iwaki S, Kast A. 1982. Repairablility of drug-induced "wavy ribs" in rat offspring. Arzneim.-Forsch./Drug Res 32(II): 1518-1522.
14. Novartis Ritalin®, Ritalin-SR®. 2001. Novartis Ritalin® tablets, Ritalin-SR® sustained-release product labeling. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
15. Patrick KS, Caldwell RW, Ferris RM, Breese GR. 1987. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241:152-158.
16. Srinivas NR, Hubbard JW, Quinn D, Midha KK. 1992. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther 52:561-568.
17. Staples RE. 1974. Detection of visceral alterations in mammalian fetuses. Teratology 9(3):A37.
18. Staples RE, Schnell, VL. 1964. Refinements in rapid clearing technique in the KOH-alizarin red S method for fetal bone. Stain Technology 39:61-63.
19. Teo SK, Stirling, DI, Hoberman AM, Christian MS, Thomas SD, Khetani VD. 2003. D-methylphenidate and d,l-methylphenidate are not development toxicants in rats and rabbits. Birth Defects Res Part B Dev Reprod Toxicol 68: 162-171.
20. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, et al. 1983. Pharmacokinetics of methylphenidate in man, rat, and monkey. J Pharm Exper Ther 226:382-386.
21. Wilson JG. 1965. Methods for administering agents and detecting malformations in experimental animals. Teratology: Principles and Techniques, 262-277.
22. Winer BJ. 1971. Statistical Principles in Experimental Design, 2nd ed. New York: McGraw-Hill.